Brian G. Mitchell, PharmD, BCPS, BCPP

  • 5Articles
  • 34.1KReads
  • 2017–2024Active
  • 13Collaborators
  • 10Citations

About

Brian G. Mitchell, PharmD, BCPS, BCPP, is affiliated with the Menninger Department of Psychiatry and Behavioral Sciences at Baylor College of Medicine in Houston, Texas. Between 2017 and 2024, Mitchell has published extensively on schizophrenia, schizoaffective disorders, bipolar disorder, and psychiatric issues affecting veterans and military populations. His work includes case reports and studies on topics such as clozapine treatment in veterans, lithium serum concentration changes, neuroleptic malignant syndrome, and psychotic exacerbations related to medication. He frequently collaborates with co-authors including Annette Walder, Olaoluwa O. Okusaga, and Ashley L. Adams.

Publications

PCC
Caffeine Reduction Increases Serum Lithium Concentration
Case Report

Caffeine Reduction Increases Serum Lithium Concentration

April 11, 2024

A patient with schizoaffective disorder was found to have supratherapeutic lithium serum concentrations following sudden caffeine reduction, and management with lithium dosage reduction precipitated exacerbation of psychiatric symptomatology.
, , , et al
PCC
History of Suicide Attempt and Clozapine in Veterans With Schizophrenia
Original Research

History of Suicide Attempt and Clozapine in Veterans With Schizophrenia

November 1, 2022

This study evaluated whether a history of suicide attempt increases the odds of receiving clozapine treatment in veterans with schizophrenia or schizoaffective disorder.
, , , et al
JCP
Brief Report

Clozapine Is Associated With Higher COVID-19 Infection Rate in Veterans With Schizophrenia

August 24, 2021

Does clozapine treatment increase the odds of testing positive for COVID-19? This small study of a VA patient population posed the question.
, , , et al
PCC
Letter to the Editor

Neuroleptic Malignant Syndrome and Risperidone

November 30, 2017

Neuroleptic malignant syndrome is a severe idiosyncratic and potentially life-threatening adverse effect of antipsychotic therapy characterized by fever, rigidity, altered mental status, creatine kinase elevation, and autonomic instability. Here,...
, ,
PCC
Letter to the Editor

Psychotic Exacerbation Following Subcutaneous Leuprolide

April 6, 2017

Could leuprolide therapy cause a worsening of psychosis after an extended period of psychiatric stability? Here, read about a man with prior history of paranoid schizophrenia who experienced an...
, ,

Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Learn More About Psychedelics in Psychiatry

Explore the Collection
Neural network illustration symbolizing psychedelic research advancements

Subscribe to read
more articles

Subscribe